Efficacy and safety of trifluridine/tipiracil (FTD/TPI) in European patients with heavily pretreated metastatic gastric cancer (mGC): An analysis of the TAGS study

dc.contributor.author	Alsina, M
dc.contributor.author	Tabernero, J
dc.contributor.author	Arkenau, HT
dc.contributor.author	Squadroni, M
dc.contributor.author	Doi, T
dc.contributor.author	Faustino, C
dc.contributor.author	Ghidini, M
dc.contributor.author	Mansoor, Was
dc.contributor.author	Shitara, K
dc.contributor.author	Van Cutsem, E
dc.contributor.author	Causse-Amellal, N
dc.contributor.author	Leger, C
dc.contributor.author	Skanji, D
dc.contributor.author	Ilson, D
dc.date.accessioned	2019-12-09T17:08:12Z
dc.date.available	2019-12-09T17:08:12Z
dc.date.issued	2019	en
dc.identifier.citation	Alsina M, Tabernero J, Arkenau HT, Squadroni M, Doi T, Faustino C, et al. 801P Efficacy and safety of trifluridine/tipiracil (FTD/TPI) in European patients with heavily pretreated metastatic gastric cancer (mGC): An analysis of the TAGS study. Annals of Oncology. 2019;30(Supplement_5).	en
dc.identifier.doi	10.1093/annonc/mdz247.127	en
dc.identifier.uri	http://hdl.handle.net/10541/622522
dc.language.iso	en	en
dc.relation.url	https://dx.doi.org/10.1093/annonc/mdz247.127	en
dc.title	Efficacy and safety of trifluridine/tipiracil (FTD/TPI) in European patients with heavily pretreated metastatic gastric cancer (mGC): An analysis of the TAGS study	en
dc.type	Meetings and Proceedings	en
dc.contributor.department	Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona	en
dc.identifier.journal	Annals of Oncology	en
dc.description.note		en
refterms.dateFOA	2020-01-22T19:53:25Z

Name:

mdz247.127.pdf

Size:

88.01Kb

Format:

PDF

Description:

From UNPAYWALL. Conference abstract